Skip to main content
. 2019 Aug 31;41(2):209–217. doi: 10.1093/eurheartj/ehz621

Take home figure.

Take home figure

The key observations of this article. Upper panel: relationship between occurrence vs. non-occurrence of hypoglycaemia and select outcomes in the placebo group of EMPA-REG OUTCOME. Lower panel: Effect of empagliflozin on select outcomes in the total population and by occurrence of hypoglycaemia in EMPA-REG OUTCOME. Hypoglycaemia defined as symptomatic hypoglycaemia with plasma glucose ≤70 mg/dL, any hypoglycaemia with PG <54 mg/dL, or severe hypoglycaemia.